Inhibition of MAPK-Erk pathway in vivo attenuates aortic valve disease processes in Emilin1-deficient mouse model

Keyphrases

• Mouse Model 100%
• Gene-deficient Mice 100%
• Disease Process 100%
• ERK Pathway 100%
• Aortic Valve Disease 100%
• Aortic Valve 80%
• Refametinib 80%
• Doxycycline 60%
• Elastase 40%
• Elastic Fibers 40%
• Fiber Fabrication 40%
• Valve Tissue 40%
• Elastic Fiber Fragmentation 40%
• Disease Progression 20%
• RNA-seq Analysis 20%
• Targeted Therapy 20%
• Fibrosis 20%
• Inflammatory Pathways 20%
• Age-matched 20%
• Glycoprotein 20%
• Treatment Strategy 20%
• ERK2 20%
• Pharmacological Inhibitors 20%
• Vascular Endothelial Growth Factor 20%
• Natural History 20%
• Promising Treatment 20%
• Assembly Error 20%
• Neutrophil Infiltration 20%
• MEK1 20%
• Matrix metalloproteinase-9 (MMP-9) 20%
• Pharmacological Therapy 20%
• Neovascularization 20%
• Elastase Activity 20%
• Elastolytic Activity 20%
• Abnormal Angiogenesis 20%
• Adult Stage 20%
• Macrophage Infiltration 20%
• Cathepsin K 20%
• Matrix metalloproteinase-2 (MMP-2) 20%
• Elastase Inhibitor 20%

Medicine and Dentistry

• Disease Process 100%
• Mitogen-Activated Protein Kinase 100%
• Aortic Valve Disease 100%
• Aortic Valve 80%
• Elastic Fiber 80%
• Refametinib 80%
• Doxycycline 60%
• Elastase 60%
• Upregulation 20%
• Macrophage 20%
• Targeted Therapy 20%
• Fibrosis 20%
• Disease Exacerbation 20%
• Angiogenesis 20%
• Neutrophil Chemotaxis 20%
• Gelatinase B 20%
• Glycoprotein 20%
• Vasculotropin A 20%
• Gelatinase A 20%
• Elastase Inhibitor 20%
• Cathepsin K 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse Model 100%
• Aortic Valve Disease 100%
• Refametinib 80%
• Doxycycline 60%
• Elastase 60%
• Fibrosis 20%
• Disease Exacerbation 20%
• Glycoprotein 20%
• Gelatinase B 20%
• Neovascularization (Pathology) 20%
• Gelatinase A 20%
• Elastase Inhibitor 20%
• Vasculotropin A 20%
• Cathepsin K 20%